(2008). Ankle Brachial Index Collaboration, Fowkes FG, Murray GD et al.: a meta-analysis. JAMA 300:197–208,
(2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829–1839,
(2007). Erqou S et al.: The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inﬂammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.
(2008). GD: The association of C-reactive protein and CRP genotype with coronary heart disease: ﬁndings from ﬁve studies with 4,610 cases amongst 18,637 participants. PLoS ONE 3:e3011,
(2008). Genetics Collaboration. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation.
(2008). Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
(2008). Hingorani AD: Bayesian meta-analysis of genetic association studies with different sets of markers.
(2008). Hingorani AD: Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts.
Humphries S: Nature’s randomised trials.
(2006). Insight into the nature of the CRP-coronary event association using Mendelian randomization.
(2008). Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5:e78,
(2006). Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 145:35–42,
(2008). Nordestgaard BG: Genetically elevated C-reactive protein and ischemic vascular disease.
(2009). PC: C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 58:926–933,
(2006). Pepys MB: C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 8:421–428,
Pepys MB: C-reactive protein and coronary heart disease: a critical review.
(2008). Sattar N: Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Curr Opin Lipidol 19:563–571,
Sick individuals and sick populations.
(2006). SP: Targeting C-reactive protein for the treatment of cardiovascular disease.
(2007). Witteman JC: C-reactive protein is related to extent and progression of coronary and extracoronary atherosclerosis: results from the Rotterdam study. Atherosclerosis 195:e195–e202,